Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

Author:

Will Britta1,Kawahara Masahiro1,Luciano Julia P.1,Bruns Ingmar2,Parekh Samir3,Erickson-Miller Connie L.4,Aivado Manuel A.4,Verma Amit35,Steidl Ulrich1

Affiliation:

1. Department of Cell Biology and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY;

2. Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany;

3. Department of Medicine, Albert Einstein College of Medicine, Bronx, NY;

4. GlaxoSmithKline, Collegeville, PA; and

5. Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY

Abstract

Abstract Thrombocytopenia is a frequent symptom and clinical challenge in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Eltrombopag is a small molecule thrombopoietin receptor agonist that might be a new option to treat thrombocytopenia in these diseases, provided that it does not stimulate malignant hematopoiesis. In this work, we studied the effects of Eltrombopag on proliferation, apoptosis, differentiation, colony formation, and malignant self-renewal of bone marrow mononuclear cells of patients with AML and MDS. Malignant bone marrow mononuclear cells did not show increased proliferation, or increased clonogenic capacity at concentrations of Eltrombopag ranging from 0.1 to 30 μg/mL. On the contrary, we observed a moderate, statistically nonsignificant (P = .18), decrease of numbers of malignant cells (mean, 56%; SD, 28%). Eltrombopag neither led to increased 5-bromo-2-deoxyuridine incorporation, decreased apoptosis, an increase of malignant self-renewal, nor enhanced in vivo engraftment in xenotransplantations. Furthermore, we found that Eltrombopag was capable of increasing megakaryocytic differentiation and formation of normal megakaryocytic colonies in patients with AML and MDS. These results provide a preclinical rationale for further testing of Eltrombopag for treatment of thrombocytopenia in AML and MDS.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Reference31 articles.

1. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.;Hellström-Lindberg;Semin Hematol,2008

2. The incidence and impact of thrombocytopenia in myelodysplastic syndromes.;Kantarjian;Cancer,2007

3. Survival, hospitalization and cause of death in 99 patients with the myelodysplastic syndrome.;Konstantopoulos;Anticancer Res,1989

4. Myelodysplastic syndromes: a clinical and pathologic analysis of 109 cases.;Foucar;Cancer,1985

5. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes.;Aul;Br J Haematol,1992

Cited by 119 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3